In triple-negative breast cancer, the C-terminal HSP90 inhibitor L80 effectively reduces the cell proliferation, breast cancer stemness, tumor growth, and metastasis by inhibiting AKT/MEK/ERK/JAK2/STAT3 signaling, while not affecting normal cells [208]. The gene discussed is AKT1; the disease is neoplasm.